- Home
- CEPV vs CADL Comparison
CEPV vs CADL Comparison
Compare CEPV & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPV | CADL |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | N/A | 55 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.4M | 357.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CEPV | CADL |
|---|---|---|
| Price | $10.11 | $4.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.71 |
| AVG Volume (30 Days) | 54.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.09 | $4.25 |
| 52 Week High | $10.35 | $7.24 |
Technical Indicators
Market Signals| Indicator | CEPV | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 42.63 |
| Support Level | N/A | $4.58 |
| Resistance Level | $10.17 | $5.42 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 28.15 |
Price Performance
Historical ComparisonAbout CEPV Cantor Equity Partners V Inc. Class A Ordinary Shares
Cantor Equity Partners V Inc is a blank check company.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.